000156030 001__ 156030
000156030 005__ 20240328115555.0
000156030 0247_ $$2doi$$a10.1002/hbm.25393
000156030 0247_ $$2pmid$$apmid:33638213
000156030 0247_ $$2pmc$$apmc:PMC8090788
000156030 0247_ $$2ISSN$$a1065-9471
000156030 0247_ $$2ISSN$$a1097-0193
000156030 0247_ $$2altmetric$$aaltmetric:100970449
000156030 037__ $$aDZNE-2021-01162
000156030 041__ $$aEnglish
000156030 082__ $$a610
000156030 1001_ $$0P:(DE-HGF)0$$aRuppert, Marina C$$b0
000156030 245__ $$aThe default mode network and cognition in Parkinson's disease: A multimodal resting-state network approach.
000156030 260__ $$aNew York, NY$$bWiley-Liss$$c2021
000156030 3367_ $$2DRIVER$$aarticle
000156030 3367_ $$2DataCite$$aOutput Types/Journal article
000156030 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711545923_24243
000156030 3367_ $$2BibTeX$$aARTICLE
000156030 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156030 3367_ $$00$$2EndNote$$aJournal Article
000156030 520__ $$aInvolvement of the default mode network (DMN) in cognitive symptoms of Parkinson's disease (PD) has been reported by resting-state functional MRI (rsfMRI) studies. However, the relation to metabolic measures obtained by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) is largely unknown. We applied multimodal resting-state network analysis to clarify the association between intrinsic metabolic and functional connectivity abnormalities within the DMN and their significance for cognitive symptoms in PD. PD patients were classified into normal cognition (n = 36) and mild cognitive impairment (MCI; n = 12). The DMN was identified by applying an independent component analysis to FDG-PET and rsfMRI data of a matched subset (16 controls and 16 PD patients) of the total cohort. Besides metabolic activity, metabolic and functional connectivity within the DMN were compared between the patients' groups and healthy controls (n = 16). Glucose metabolism was significantly reduced in all DMN nodes in both patient groups compared to controls, with the lowest uptake in PD-MCI (p < .05). Increased metabolic and functional connectivity along fronto-parietal connections was identified in PD-MCI patients compared to controls and unimpaired patients. Functional connectivity negatively correlated with cognitive composite z-scores in patients (r = -.43, p = .005). The current study clarifies the commonalities of metabolic and hemodynamic measures of brain network activity and their individual significance for cognitive symptoms in PD, highlighting the added value of multimodal resting-state network approaches for identifying prospective biomarkers.
000156030 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000156030 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000156030 650_7 $$2Other$$aParkinson's disease
000156030 650_7 $$2Other$$a[18F]-FDG-PET
000156030 650_7 $$2Other$$adefault mode network
000156030 650_7 $$2Other$$ametabolic covariance
000156030 650_7 $$2Other$$amild cognitive impairment
000156030 650_7 $$2Other$$aresting-state fMRI
000156030 650_2 $$2MeSH$$aAged
000156030 650_2 $$2MeSH$$aCerebral Cortex: diagnostic imaging
000156030 650_2 $$2MeSH$$aCerebral Cortex: metabolism
000156030 650_2 $$2MeSH$$aCerebral Cortex: physiopathology
000156030 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000156030 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000156030 650_2 $$2MeSH$$aCognitive Dysfunction: metabolism
000156030 650_2 $$2MeSH$$aCognitive Dysfunction: physiopathology
000156030 650_2 $$2MeSH$$aConnectome
000156030 650_2 $$2MeSH$$aDefault Mode Network: diagnostic imaging
000156030 650_2 $$2MeSH$$aDefault Mode Network: metabolism
000156030 650_2 $$2MeSH$$aDefault Mode Network: physiopathology
000156030 650_2 $$2MeSH$$aFemale
000156030 650_2 $$2MeSH$$aHumans
000156030 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000156030 650_2 $$2MeSH$$aMale
000156030 650_2 $$2MeSH$$aMiddle Aged
000156030 650_2 $$2MeSH$$aMultimodal Imaging
000156030 650_2 $$2MeSH$$aParkinson Disease: complications
000156030 650_2 $$2MeSH$$aParkinson Disease: diagnostic imaging
000156030 650_2 $$2MeSH$$aParkinson Disease: metabolism
000156030 650_2 $$2MeSH$$aParkinson Disease: physiopathology
000156030 650_2 $$2MeSH$$aPositron-Emission Tomography
000156030 7001_ $$aGreuel, Andrea$$b1
000156030 7001_ $$aFreigang, Julia$$b2
000156030 7001_ $$aTahmasian, Masoud$$b3
000156030 7001_ $$aMaier, Franziska$$b4
000156030 7001_ $$aHammes, Jochen$$b5
000156030 7001_ $$0P:(DE-2719)2812285$$aEimeren, Thilo$$b6$$udzne
000156030 7001_ $$aTimmermann, Lars$$b7
000156030 7001_ $$aTittgemeyer, Marc$$b8
000156030 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b9$$udzne
000156030 7001_ $$aEggers, Carsten$$b10
000156030 773__ $$0PERI:(DE-600)1492703-2$$a10.1002/hbm.25393$$gVol. 42, no. 8, p. 2623 - 2641$$n8$$p2623 - 2641$$tHuman brain mapping$$v42$$x1097-0193$$y2021
000156030 8564_ $$uhttps://pub.dzne.de/record/156030/files/DZNE-2021-01162.pdf$$yOpenAccess
000156030 8564_ $$uhttps://pub.dzne.de/record/156030/files/DZNE-2021-01162.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000156030 909CO $$ooai:pub.dzne.de:156030$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000156030 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812285$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000156030 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000156030 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000156030 9141_ $$y2021
000156030 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000156030 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-27T20:46:01Z
000156030 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bHUM BRAIN MAPP : 2021$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-27$$wger
000156030 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000156030 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000156030 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-27T20:46:01Z
000156030 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000156030 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHUM BRAIN MAPP : 2021$$d2022-11-22
000156030 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000156030 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-22$$wger
000156030 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-22
000156030 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x0
000156030 9201_ $$0I:(DE-2719)1011101$$kPatient Studies Bonn$$lPatient Studies Bonn$$x1
000156030 980__ $$ajournal
000156030 980__ $$aVDB
000156030 980__ $$aUNRESTRICTED
000156030 980__ $$aI:(DE-2719)1011202
000156030 980__ $$aI:(DE-2719)1011101
000156030 9801_ $$aFullTexts